A centre for development of the next generation NK cell-based immunotherapies against cancer to be built from Karolinska Institutet.
Register for our finance events and AdBIOPRO bioreactor course
KARO1 is the first GMP hESC line produced at Vecura, there are more to come!
Real examples of taking ATMPs from research to market approval. Who do you need to be partnering with!?
Swedish gene therapy clinical trial for RLBP1 Retinitis Pigmentosa ongoing in Stockholm, Sweden
Sweden drives National and International collaboration to improve quality of life for burns survivors, saved through skin stem cell transplants
The Conference edition of our Newsletter! Read more about the success that was ATMP Sweden 2019!
The era of gene and cell therapy treatments is here!
Advanced therapies for future Healthcare
Good news from of one of our CAMP Projects "Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor".
We are pleased to hear that Johan Hyllner has been recruited to AstraZeneca as Head of their Cell and Gene Therapy program.
VOG (tissue area Group) cell represents a National network of University hospitals in Sweden.
It's too cold to go outside, browse our newsletter instead!
Cobra is currently expanding capacity in both Keele, UK and Matfors, Sweden.
We caught up with Johan to see what his plans are post Catapult.
As part of CAMP WP1/WP2 Karolinska Institutet is setting up a pre-GMP core facility.
Welcome to the first CAMP/Swelife-ATMP quarterly ATMP newsletter!